Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach.

Adel, Nada; Mantawy, Eman M; El-Sherbiny, Doaa A; El-Demerdash, Ebtehal

Adel, Nada; Mantawy, Eman M; El-Sherbiny, Doaa A; El-Demerdash, Ebtehal.

Affiliation

Adel N; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mantawy EM; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
El-Sherbiny DA; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
El-Demerdash E; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address: ebtehal_dm@pharma.asu.edu.eg.

Toxicol Appl Pharmacol ; 382: 114748, 2019 11 01.

Article in En | MEDLINE | ID: mdl-31499193

Subject(s)

Concanavalin A/toxicity; Deferasirox/therapeutic use; Iron Chelating Agents/therapeutic use; Iron Overload/prevention & control; Liver Cirrhosis/prevention & control; Animals; Iron Overload/chemically induced; Iron Overload/metabolism; Liver Cirrhosis/chemically induced; Liver Cirrhosis/metabolism; Male; Rats; Rats, Sprague-Dawley

Key words

Concanavalin A; Deferasirox; Hepcidin; Iron overload; Liver fibrosis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Iron Chelating Agents / Concanavalin A / Iron Overload / Deferasirox / Liver Cirrhosis Limits: Animals Language: En Journal: Toxicol Appl Pharmacol Year: 2019 Type: Article Affiliation country: Egypt

Fulltext

XML

PubMed Links

Search on Google